Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

[1]  JeffreyGroup.  ANVISA aprova novo tratamento para câncer de próstata , 2022, Revista Feridas.

[2]  T. Tammela,et al.  Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. , 2020, The New England journal of medicine.

[3]  Steven C. R. Williams,et al.  Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers. , 2020 .

[4]  P. Kantoff,et al.  Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. , 2020, European urology.

[5]  M. Botteman,et al.  Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan. , 2019, Future oncology.

[6]  T. Tammela,et al.  Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial , 2019, Targeted Oncology.

[7]  N. Masumori,et al.  The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer patients from the Medical Data Vision claims database in Japan , 2019, Current medical research and opinion.

[8]  T. Tammela,et al.  Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC). , 2019, Journal of Clinical Oncology.

[9]  D. Seidel,et al.  Higher blood–brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography. , 2019, Journal of Clinical Oncology.

[10]  G. Garg,et al.  Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: A comprehensive review. , 2019, Turkish journal of urology.

[11]  T. Tammela,et al.  Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.

[12]  W. Oyen,et al.  Managing Nonmetastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[13]  E. Small,et al.  Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation. , 2018, Annals of Oncology.

[14]  M. Lorentzon,et al.  Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures—a study from the fractures and fall injuries in the elderly cohort (FRAILCO) , 2018, Osteoporosis International.

[15]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[16]  Xianglin L. Du,et al.  Risks of Major Long‐Term Side Effects Associated with Androgen‐Deprivation Therapy in Men with Prostate Cancer , 2018, Pharmacotherapy.

[17]  F. Saad,et al.  Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.

[18]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[19]  Thomas Wiegel,et al.  Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. , 2018, European urology.

[20]  T. Tammela,et al.  Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. , 2017, European urology focus.

[21]  H. Mukai,et al.  Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer , 2017, Cancer Chemotherapy and Pharmacology.

[22]  B. Tombal,et al.  Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer , 2017, Medicine.

[23]  Y. Kakehi,et al.  Evidenced‐based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition) , 2017, International journal of urology : official journal of the Japanese Urological Association.

[24]  E. Small,et al.  Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment , 2017, Expert review of anticancer therapy.

[25]  T. Tammela,et al.  Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials. , 2017, European urology focus.

[26]  M. Yao,et al.  Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score , 2016, BMC Urology.

[27]  Choung-Soo Kim,et al.  The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients , 2016, Investigative and clinical urology.

[28]  T. Beer,et al.  Treatment of Nonmetastatic Castration-Resistant Prostate Cancer. , 2016, Oncology.

[29]  J. Palvimo,et al.  Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies , 2015, Scientific Reports.

[30]  T. Tammela,et al.  Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. , 2014, The Lancet. Oncology.

[31]  J. Concato,et al.  Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment. , 2014, Journal of geriatric oncology.

[32]  A. Liede,et al.  International prevalence of nonmetastatic (M0) castration-resistant prostate cancer (CRPC). , 2013 .

[33]  H. Akaza,et al.  Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score , 2013, Prostate international.

[34]  L. Holmberg,et al.  Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. , 2012, European journal of cancer.

[35]  H. Morgenstern,et al.  Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States , 2012, Pharmacoepidemiology and drug safety.

[36]  Henrik Toft Sørensen,et al.  Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). , 2010, The Journal of urology.

[37]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[38]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  H. Miwa.  Prevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria , 2008, Patient preference and adherence.

[40]  F. Saad,et al.  Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Foxx-Orenstein,et al.  Chronic Constipation in the Elderly , 2012, The American Journal of Gastroenterology.